Faculty Listing By Sites

David Daikh, MD

4150 Clement St
San Francisco, CA 94121
415-750-2104 ext. 3387

Dr. Daikh is the Rheumatology Division Chief at the SFVA Medical Center, and director of the rheumatology fellowship program at UCSF. Dr. Daikh's research focuses on immune mechanisms of rheumatic disease, and he directs a core laboratory that serves a number of investigators at UCSF. Dr. Daikh is also the President of the Rheumatology Research Foundation.

Related Web Sites

Recent Articles (40)

  1. van der Heijde D, Daikh DI, Betteridge N, Burmester GR, Hassett AL, Matteson EL, van Vollenhoven R, Lakhanpal S. Common Language Description of the Term Rheumatic and Musculoskeletal Diseases (RMDs) for Use in Communication With the Lay Public, Healthcare Providers, and Other Stakeholders Endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). Arthritis Rheumatol. 2018 Mar 13.

  2. van der Heijde D, Daikh DI, Betteridge N, Burmester GR, Hassett AL, Matteson EL, van Vollenhoven R, Lakhanpal S. Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). Ann Rheum Dis. 2018 Mar 10.

  3. Tedeschi SK, Johnson SR, Boumpas D, Daikh D, Dörner T, Jayne D, Kamen D, Lerstrøm K, Mosca M, Ramsey-Goldman R, Sinnette C, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH. Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. Arthritis Care Res (Hoboken). 2018 Apr; 70(4):571-581.

  4. Leuchten N, Hoyer A, Brinks R, Schoels M, Schneider M, Smolen J, Johnson SR, Daikh D, Dörner T, Aringer M, Bertsias G. Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. Arthritis Care Res (Hoboken). 2018 Mar; 70(3):428-438.

  5. Leuchten N, Milke B, Winkler-Rohlfing B, Daikh D, Dörner T, Johnson SR, Aringer M. Early symptoms of systemic lupus erythematosus (SLE) recalled by 339 SLE patients. Lupus. 2018 Jan 01; 961203318776093.

  6. Schmajuk G, Hoyer BF, Aringer M, Johnson SR, Daikh DI, Dörner T. Multi-center Delphi Exercise Reveals Important Key Items for Classifying Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2017 Dec 29.

  7. Daikh DI, Costenbader KH. How Do We Classify "Incomplete Lupus?" Arthritis Care Res (Hoboken). 2017 Dec; 69(12):1777-1779.

  8. Schmajuk G, Tonner C, Miao Y, Yazdany J, Gannon J, Boscardin WJ, Daikh DI, Steinman MA. Folic Acid Supplementation Is Suboptimal in a National Cohort of Older Veterans Receiving Low Dose Oral Methotrexate. PLoS One. 2016; 11(12):e0168369.

  9. Andrews JS, Trupin L, Hough CL, Daikh DI, Yelin EH, Katz PP. Serum biomarkers of inflammation and muscle strength among women with systemic lupus erythematosus. Cytokine. 2017 02; 90:109-112.

  10. Bays A, Wahl E, Daikh DI, Yazdany J, Schmajuk G. Implementation of disease activity measurement for rheumatoid arthritis patients in an academic rheumatology clinic. BMC Health Serv Res. 2016 08 15; 16(a):384.

  11. Daikh DI, Chen PP. Advances in managing ankylosing spondylitis. F1000Prime Rep. 2014; 6:78.

  12. Schmajuk G, Miao Y, Yazdany J, Boscardin WJ, Daikh DI, Steinman MA. Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record. Arthritis Care Res (Hoboken). 2014 Aug; 66(8):1159-66.

  13. Yazdany J, Schmajuk G, Robbins M, Daikh D, Beall A, Yelin E, Barton J, Carlson A, Margaretten M, Zell J, Gensler LS, Kelly V, Saag K, King C. Choosing wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question. Arthritis Care Res (Hoboken). 2013 Mar; 65(3):329-39.

  14. Mohr DC, Lovera J, Brown T, Cohen B, Neylan T, Henry R, Siddique J, Jin L, Daikh D, Pelletier D. A randomized trial of stress management for the prevention of new brain lesions in MS. Neurology. 2012 Jul 31; 79(5):412-9.

  15. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, Ramsey-Goldman R, Singh K, Khalighi M, Choi SI, Gogia M, Kafaja S, Kamgar M, Lau C, Martin WJ, Parikh S, Peng J, Rastogi A, Chen W, Grossman JM. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012 Jun; 64(6):797-808.

  16. Daikh DI, St Clair EW. Updated recommendations for the treatment of rheumatoid arthritis: another step on a long road. Arthritis Care Res (Hoboken). 2012 May; 64(5):648-51.

  17. Ashouri JF, Daikh DI. Rheumatic manifestations of cancer. Rheum Dis Clin North Am. 2011 Nov; 37(4):489-505.

  18. Charles JF, Eberle C, Daikh DI, Rooney T. Resolution of recurrent fusarium arthritis after prolonged antifungal therapy. J Clin Rheumatol. 2011 Jan; 17(1):44-5.

  19. Scalapino KJ, Daikh DI. Suppression of glomerulonephritis in NZB/NZW lupus prone mice by adoptive transfer of ex vivo expanded regulatory T cells. PLoS One. 2009 Jun 24; 4(6):e6031.

  20. Gupta VA, Hermiston ML, Cassafer G, Daikh DI, Weiss A. B cells drive lymphocyte activation and expansion in mice with the CD45 wedge mutation and Fas deficiency. J Exp Med. 2008 Nov 24; 205(12):2755-61.

  21. Scalapino KJ, Daikh DI. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev. 2008 Jun; 223:143-55.

  22. Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, Chang B, Zhao FF, Payan DG, Grossbard EB, Daikh DI. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum. 2008 May; 58(5):1433-44.

  23. Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B, Jones KD, King TE. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med. 2007 Oct 01; 176(7):691-7.

  24. Buxbaum J, Qian P, Khuu C, Shneider BL, Daikh DI, Gershwin ME, Allen PM, Peters MG. Novel model of antigen-specific induction of bile duct injury. Gastroenterology. 2006 Dec; 131(6):1899-906.

  25. Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML, Daikh DI. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol. 2006 Aug 01; 177(3):1451-9.

  26. Daikh DI, Gillis J, Wofsy D. Inhibition of T cell costimulation: an emerging therapeutic strategy for autoimmune rheumatic diseases. Arthritis Rheum. 2006 Apr 15; 55(2):322-4.

  27. Daikh DI. The Vioxx debacle revisited. Am J Med. 2005 Sep; 118(9):1057.

  28. Davidson A, Diamond B, Wofsy D, Daikh D. Block and tackle: CTLA4Ig takes on lupus. Lupus. 2005; 14(3):197-203.

  29. Cunnane G, Chan OT, Cassafer G, Brindis S, Kaufman E, Yen TS, Daikh DI. Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide. Arthritis Rheum. 2004 May; 50(5):1539-48.

  30. Cunnane G, Warnock M, Fye KH, Daikh DI. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum. 2002 Aug; 47(4):445-9.

  31. Schumacher HR, Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, Tate GA, Molina J. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ. 2002 Jun 22; 324(7352):1488-92.

  32. Wofsy D, Daikh DI. Treatment of autoimmune diseases by inhibition of T-cell costimulation. Mod Rheumatol. 2002 Mar; 12(1):1-4.

  33. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol. 2001 Mar 01; 166(5):2913-6.

  34. Daikh DI, Wofsy D. Treatment of autoimmunity by inhibition of T cell costimulation. Adv Exp Med Biol. 2001; 490:113-7.

  35. Majeti R, Xu Z, Parslow TG, Olson JL, Daikh DI, Killeen N, Weiss A. An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell. 2000 Dec 22; 103(7):1059-70.

  36. Daikh DI, Wofsy D. Effects of anti-B7 monoclonal antibodies on humoral immune responses. J Autoimmun. 1999 Mar; 12(2):101-8.

  37. Daikh DI, Wofsy D. On the horizon: clinical trials of new immunosuppressive strategies for autoimmune diseases. Transplant Proc. 1998 Dec; 30(8):4027-8.

  38. Wofsy D, Daikh DI. Opportunities for future biological therapy in SLE. Baillieres Clin Rheumatol. 1998 Aug; 12(3):529-41.

  39. Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol. 1997 Oct 01; 159(7):3104-8.

  40. Daikh D, Wofsy D, Imboden JB. The CD28-B7 costimulatory pathway and its role in autoimmune disease. J Leukoc Biol. 1997 Aug; 62(2):156-62.

  Select data provided by UCSF Profiles, powered by CTSI at UCSF. Learn more about the data source.